{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:36:15Z","timestamp":1787002575905,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00422023"],"award-info":[{"award-number":["RS-2024-00422023"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-00514209"],"award-info":[{"award-number":["RS-2025-00514209"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Muscle-invasive bladder cancer (MIBC) presents with variable clinical and pathological features, leading to inconsistent responses to standard treatments such as neoadjuvant chemotherapy (NAC). Although transcriptome profiling has shown differences in NAC response, reliable predictors of treatment outcome remain elusive. Here this study aimed to improve NAC response prediction by integrating multicohort transcriptomic data and spatial protein expression profiles using machine learning, enabling precision diagnostics and therapeutic strategies. Transcriptome analysis from four independent cohorts (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009399) using diverse gene classifiers revealed molecular features associated with NAC response, particularly genes involved in stress responses, immunity and cell adhesion. The clinical relevance of 74 markers was validated by digital pathology for analyzing spatial protein expression. The machine learning frameworks reduced complex transcriptome and digital pathology datasets to a clinically manageable number of biomarkers, yielding an optimal antibody panel for immunohistochemistry-based clinical diagnostics. Computational pathology-driven predictions of NAC response demonstrated a strong correlation with survival outcomes in patients with MIBC, highlighting their potential clinical utility. Mechanistically, targeting the KEAP1\u2013NRF2 axis suppressed glutathione dynamics, proliferation, stemness features and invasiveness of cisplatin-resistant MIBC cells, thereby resensitizing them to cisplatin. Combination treatment with cisplatin and inhibitors targeting the KEAP1\u2013NRF2 pathway markedly suppressed tumor growth in an orthotopic xenograft model. Therefore, this study integrates machine learning-based transcriptome profiling and digital pathology analysis to refine gene classifiers, provide a personalized and feasible framework for treatment decision-making, and overcome chemoresistance to improve therapeutic efficacy.\n                  <\/jats:p>","DOI":"10.1038\/s12276-026-01718-y","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:35:10Z","timestamp":1778229310000},"page":"1589-1607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Machine learning-based integration of transcriptome and digital pathology for predicting chemoresistance in muscle-invasive bladder cancer"],"prefix":"10.1038","volume":"58","author":[{"given":"Jinahn","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gowun","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0621-5937","authenticated-orcid":false,"given":"YongHwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyein","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jun","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Ji","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja-Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Un","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Gi","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Ji","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyungu","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Woo","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dabin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inkeun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Lyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bumsik","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Mee","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0511-5750","authenticated-orcid":false,"given":"Dong-Myung","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"1718_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s12276-022-00786-0","volume":"54","author":"J Heo","year":"2022","unstructured":"Heo, J. et al. The CDK1\/TFCP2L1\/ID2 cascade offers a novel combination therapy strategy in a preclinical model of bladder cancer. Exp. Mol. Med. 54, 801\u2013811 (2022).","journal-title":"Exp. Mol. Med."},{"key":"1718_CR2","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910880","volume":"12","author":"J Heo","year":"2020","unstructured":"Heo, J. et al. Phosphorylation of TFCP2L1 by CDK1 is required for stem cell pluripotency and bladder carcinogenesis. EMBO Mol. Med. 12, e10880 (2020).","journal-title":"EMBO Mol. Med."},{"key":"1718_CR3","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/1078-0432.CCR-23-0602","volume":"30","author":"SP Lerner","year":"2024","unstructured":"Lerner, S. P. et al. Association of molecular subtypes with pathologic response, PFS, and OS in a phase II study of COXEN with neoadjuvant chemotherapy for muscle-invasive bladder cancer. Clin. Cancer Res. 30, 444\u2013449 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1718_CR4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","volume":"65","author":"F Petrelli","year":"2014","unstructured":"Petrelli, F. et al. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur. Urol. 65, 350\u2013357 (2014).","journal-title":"Eur. Urol."},{"key":"1718_CR5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s12276-024-01377-x","volume":"57","author":"J Xu","year":"2025","unstructured":"Xu, J. et al. Loss of YTHDC1 m6A reading function promotes invasiveness in urothelial carcinoma of the bladder. Exp. Mol. Med. 57, 118\u2013130 (2025).","journal-title":"Exp. Mol. Med."},{"key":"1718_CR6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420\u2013433 (2020).","journal-title":"Eur. Urol."},{"key":"1718_CR7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152\u2013165 (2014).","journal-title":"Cancer Cell"},{"key":"1718_CR8","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","volume":"72","author":"R Seiler","year":"2017","unstructured":"Seiler, R. et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur. Urol. 72, 544\u2013554 (2017).","journal-title":"Eur. Urol."},{"key":"1718_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18640-0","volume":"11","author":"A Taber","year":"2020","unstructured":"Taber, A. et al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat. Commun. 11, 4858 (2020).","journal-title":"Nat. Commun."},{"key":"1718_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","volume":"81","author":"G Sjodahl","year":"2022","unstructured":"Sjodahl, G. et al. Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur. Urol. 81, 523\u2013532 (2022).","journal-title":"Eur. Urol."},{"key":"1718_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/path.4886","volume":"242","author":"G Sjodahl","year":"2017","unstructured":"Sjodahl, G., Eriksson, P., Liedberg, F. & Hoglund, M. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J. Pathol. 242, 113\u2013125 (2017).","journal-title":"J. Pathol."},{"key":"1718_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100382","volume":"2","author":"H Mi","year":"2021","unstructured":"Mi, H. et al. Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture. Cell Rep. Med. 2, 100382 (2021).","journal-title":"Cell Rep. Med."},{"key":"1718_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41374-020-00514-0","volume":"101","author":"M Cui","year":"2021","unstructured":"Cui, M. & Zhang, D. Y. Artificial intelligence and computational pathology. Lab. Invest. 101, 412\u2013422 (2021).","journal-title":"Lab. Invest."},{"key":"1718_CR14","doi-asserted-by":"publisher","first-page":"101224","DOI":"10.1016\/j.xcrm.2023.101224","volume":"4","author":"Y Kim","year":"2023","unstructured":"Kim, Y. et al. Glutathione dynamics is a potential predictive and therapeutic trait for neoadjuvant chemotherapy response in bladder cancer. Cell Rep. Med. 4, 101224 (2023).","journal-title":"Cell Rep. Med."},{"key":"1718_CR15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s12276-024-01180-8","volume":"56","author":"T Bae","year":"2024","unstructured":"Bae, T., Hallis, S. P. & Kwak, M. K. Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer. Exp. Mol. Med. 56, 501\u2013514 (2024).","journal-title":"Exp. Mol. Med."},{"key":"1718_CR16","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/nm.4407","volume":"23","author":"R Romero","year":"2017","unstructured":"Romero, R. et al. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat. Med. 23, 1362\u20131368 (2017).","journal-title":"Nat. Med."},{"key":"1718_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.freeradbiomed.2024.11.001","volume":"226","author":"L Fan","year":"2025","unstructured":"Fan, L. et al. LRRC45 accelerates bladder cancer development and ferroptosis inhibition via stabilizing NRF2 by competitively KEAP1 interaction. Free Radic. Biol. Med. 226, 29\u201342 (2025).","journal-title":"Free Radic. Biol. Med."},{"key":"1718_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113104","volume":"42","author":"T Aboulkassim","year":"2023","unstructured":"Aboulkassim, T. et al. A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants. Cell Rep. 42, 113104 (2023).","journal-title":"Cell Rep."},{"key":"1718_CR19","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1021\/acschembio.6b00651","volume":"11","author":"A Singh","year":"2016","unstructured":"Singh, A. et al. Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors. ACS Chem. Biol. 11, 3214\u20133225 (2016).","journal-title":"ACS Chem. Biol."},{"key":"1718_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.omtn.2023.06.001","volume":"33","author":"G Chu","year":"2023","unstructured":"Chu, G., Ji, X., Wang, Y. & Niu, H. Integrated multiomics analysis and machine learning refine molecular subtypes and prognosis for muscle-invasive urothelial cancer. Mol. Ther. Nucleic Acids 33, 110\u2013126 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1718_CR21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41746-025-01560-y","volume":"8","author":"Z Bai","year":"2025","unstructured":"Bai, Z. et al. Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning. npj Digit. Med. 8, 174 (2025).","journal-title":"npj Digit. Med."},{"key":"1718_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19313-8","volume":"11","author":"J Kong","year":"2020","unstructured":"Kong, J. et al. Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients. Nat. Commun. 11, 5485 (2020).","journal-title":"Nat. Commun."},{"key":"1718_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4132\/jptm.2024.07.13","volume":"58","author":"J Jeong","year":"2024","unstructured":"Jeong, J. et al. Artificial intelligence algorithm for neoplastic cell percentage estimation and its application to copy number variation in urinary tract cancer. J. Pathol. Transl. Med. 58, 229\u2013240 (2024).","journal-title":"J. Pathol. Transl. Med."},{"key":"1718_CR24","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/s12276-024-01243-w","volume":"56","author":"H Hwang","year":"2024","unstructured":"Hwang, H., Jeon, H., Yeo, N. & Baek, D. Big data and deep learning for RNA biology. Exp. Mol. Med. 56, 1293\u20131321 (2024).","journal-title":"Exp. Mol. Med."},{"key":"1718_CR25","first-page":"186","volume":"1","author":"E Lee","year":"2003","unstructured":"Lee, E., Kwak, C., Byun, S.-S., Lim, D. J. & Kim, J. H. Establishment and characterization of cisplatin-resistant human bladder cancer cells. Korean J. Urol. Oncol. 1, 186\u2013192 (2003).","journal-title":"Korean J. Urol. Oncol."},{"key":"1718_CR26","first-page":"413","volume":"55","author":"H Ju","year":"2023","unstructured":"Ju, H. et al. Activating transcription factor-2 supports the antioxidant capacity and ability of human mesenchymal stem cells to prevent asthmatic airway inflammation. Exp. Mol. Med. 55, 413\u2013425 (2023).","journal-title":"Exp. Mol. Med."},{"key":"1718_CR27","doi-asserted-by":"publisher","unstructured":"Kim, J. et al. The Cancer Genome Atlas Expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability. Eur. Urol. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.017 (2019).","DOI":"10.1016\/j.eururo.2019.02.017"},{"key":"1718_CR28","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.eururo.2015.08.034","volume":"69","author":"DJ McConkey","year":"2016","unstructured":"McConkey, D. J. et al. A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur. Urol. 69, 855\u2013862 (2016).","journal-title":"Eur. Urol."},{"key":"1718_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"The Cancer Genome Atlas Research Network","year":"2014","unstructured":"The Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315 (2014).","journal-title":"Nature"},{"key":"1718_CR30","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540\u2013556 (2017).","journal-title":"Cell"},{"key":"1718_CR31","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang, Z. et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45, W98\u2013W102 (2017).","journal-title":"Nucleic Acids Res."},{"key":"1718_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.113519","volume":"28","author":"H Wen","year":"2025","unstructured":"Wen, H. et al. NRF2 activation in cancer cells suppresses immune infiltration into the tumor microenvironment. iScience 28, 113519 (2025).","journal-title":"iScience"},{"key":"1718_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba1334","volume":"6","author":"J Lim","year":"2020","unstructured":"Lim, J. et al. Glutathione dynamics determine the therapeutic efficacy of mesenchymal stem cells for graft-versus-host disease via CREB1\u2013NRF2 pathway. Sci. Adv. 6, eaba1334 (2020).","journal-title":"Sci. Adv."},{"key":"1718_CR34","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.stemcr.2017.12.007","volume":"10","author":"EM Jeong","year":"2018","unstructured":"Jeong, E. M. et al. Real-time monitoring of glutathione in living cells reveals that high glutathione levels are required to maintain stem cell function. Stem Cell Rep. 10, 600\u2013614 (2018).","journal-title":"Stem Cell Rep."},{"key":"1718_CR35","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13046-023-02814-x","volume":"42","author":"C She","year":"2023","unstructured":"She, C. et al. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP\/PERK\/eIF2\u03b1-axis-mediated endoplasmic reticulum stress. J. Exp. Clin. Cancer Res. 42, 238 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1718_CR36","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/s12276-024-01268-1","volume":"56","author":"CM Lee","year":"2024","unstructured":"Lee, C. M. et al. PHGDH: a novel therapeutic target in cancer. Exp. Mol. Med. 56, 1513\u20131522 (2024).","journal-title":"Exp. Mol. Med."},{"key":"1718_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-024-03243-5","volume":"25","author":"K Stamatiou","year":"2024","unstructured":"Stamatiou, K. et al. Ki-67 is necessary during DNA replication for fork protection and genome stability. Genome Biol. 25, 105 (2024).","journal-title":"Genome Biol."},{"key":"1718_CR38","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s12282-009-0161-5","volume":"17","author":"R Nishimura","year":"2010","unstructured":"Nishimura, R., Osako, T., Okumura, Y., Hayashi, M. & Arima, N. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer 17, 269\u2013275 (2010).","journal-title":"Breast Cancer"},{"key":"1718_CR39","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13046-024-03224-3","volume":"43","author":"L Zheng","year":"2024","unstructured":"Zheng, L. et al. The KLF16\/MYC feedback loop is a therapeutic target in bladder cancer. J. Exp. Clin. Cancer Res. 43, 303 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1718_CR40","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/s12276-024-01244-9","volume":"56","author":"S Ke","year":"2024","unstructured":"Ke, S. et al. RGS19 activates the MYH9\/\u03b2-catenin\/c-Myc positive feedback loop in hepatocellular carcinoma. Exp. Mol. Med. 56, 1412\u20131425 (2024).","journal-title":"Exp. Mol. Med."},{"key":"1718_CR41","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41586-021-03512-4","volume":"594","author":"MY Lu","year":"2021","unstructured":"Lu, M. Y. et al. AI-based pathology predicts origins for cancers of unknown primary. Nature 594, 106\u2013110 (2021).","journal-title":"Nature"},{"key":"1718_CR42","doi-asserted-by":"publisher","first-page":"5281","DOI":"10.1200\/JCO.2007.12.3133","volume":"25","author":"R Glynne-Jones","year":"2007","unstructured":"Glynne-Jones, R. & Hoskin, P. Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm? J. Clin. Oncol. 25, 5281\u20135286 (2007).","journal-title":"J. Clin. Oncol."},{"key":"1718_CR43","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/MOU.0b013e328363de67","volume":"23","author":"J Bellmunt","year":"2013","unstructured":"Bellmunt, J., Pons, F. & Orsola, A. Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy. Curr. Opin. Urol. 23, 466\u2013471 (2013).","journal-title":"Curr. Opin. Urol."},{"key":"1718_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48480-1","volume":"15","author":"W Beckabir","year":"2024","unstructured":"Beckabir, W. et al. Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer. Nat. Commun. 15, 4448 (2024).","journal-title":"Nat. Commun."},{"key":"1718_CR45","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/MOU.0000000000001181","volume":"34","author":"B Englinger","year":"2024","unstructured":"Englinger, B. Molecular research in bladder cancer. Curr. Opin. Urol. 34, 225\u2013226 (2024).","journal-title":"Curr. Opin. Urol."},{"key":"1718_CR46","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N. Engl. J. Med. 391, 1773\u20131786 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1718_CR47","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1158\/1078-0432.CCR-23-3738","volume":"30","author":"WF Maguire","year":"2024","unstructured":"Maguire, W. F. et al. FDA approval summary: enfortumab vedotin plus pembrolizumab for cisplatin-ineligible locally advanced or metastatic urothelial carcinoma. Clin. Cancer Res. 30, 2011\u20132016 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1718_CR48","doi-asserted-by":"publisher","unstructured":"Jeong, J. et al. Source cords for \"AMC bladder cancer transcriptomics classifier\" Zenodo https:\/\/doi.org\/10.5281\/zenodo.14603073 (2025).","DOI":"10.5281\/zenodo.14603073"},{"key":"1718_CR49","doi-asserted-by":"publisher","unstructured":"Jeong, J. et al. Source cords for \"AMC bladder cancer protein digger\" Zenodo https:\/\/doi.org\/10.5281\/zenodo.14603168 (2025).","DOI":"10.5281\/zenodo.14603168"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01718-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01718-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01718-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:53:08Z","timestamp":1780548788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01718-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["1718"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01718-y","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of AMC (2020-0064). Patients gave informed consent for the use of samples and relevant clinical data for academic purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}